产品
编 号：F747571
分子式：C16H22O5
分子量：294.34
分子式：C16H22O5
分子量：294.34
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 1854061-16-7
产品详情
生物活性：
PF-06649298 is a sodium-coupled citrate transporter (NaCT or SLC13A5) inhibitor. PF-06649298 specifically interacts with NaCT with an IC50 value of 16.2 μM to inhibits the transport of citrate in human hepatocytes. PF-06649298 can be used for the research of regulating glucose metabolism and lipid metabolism.
体内研究：
PF-06649298 (250 mg/kg; p.o. twice a day; for 21 days) reverses glucose intolerance of high fat diet (HFD) mice.Animal Model:Mice with high fat diet (HFD) administration
Dosage:250 mg/kg
Administration:Oral gavage; 250mg/kg twice a day; for 21 days
Result:Decreased plasma glucose, hepatic triglycerides, diacylglycerides, and acyl-carnitines concentration of livers in HFD mice. Totally reversed glucose intolerance of HFD mice.
体外研究：
PF-06649298 (0-100 μM; 30 min) inhibits citrate uptaken in cells.
PF-06649298 is a sodium-coupled citrate transporter (NaCT or SLC13A5) inhibitor. PF-06649298 specifically interacts with NaCT with an IC50 value of 16.2 μM to inhibits the transport of citrate in human hepatocytes. PF-06649298 can be used for the research of regulating glucose metabolism and lipid metabolism.
体内研究：
PF-06649298 (250 mg/kg; p.o. twice a day; for 21 days) reverses glucose intolerance of high fat diet (HFD) mice.Animal Model:Mice with high fat diet (HFD) administration
Dosage:250 mg/kg
Administration:Oral gavage; 250mg/kg twice a day; for 21 days
Result:Decreased plasma glucose, hepatic triglycerides, diacylglycerides, and acyl-carnitines concentration of livers in HFD mice. Totally reversed glucose intolerance of HFD mice.
体外研究：
PF-06649298 (0-100 μM; 30 min) inhibits citrate uptaken in cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备